Skip to main content
. Author manuscript; available in PMC: 2011 Nov 1.
Published in final edited form as: Pharmacol Biochem Behav. 2010 May 15;97(1):138–143. doi: 10.1016/j.pbb.2010.05.010

Figure 3.

Figure 3

Evoked DA release is altered by bupropion but not by MSI-1436 or saline. DA release was evoked once every 5min for 15 samples. (a.) The magnitude of evoked release (peak height) was normalized for each rat and expressed as percent change from the average of the 3 baseline samples. The known reuptake blocker bupropion (filled circles) caused a significant increase in peak height 5min after injection through the duration of the experiment. Injection of either saline (open circles) or MSI-1436 (closed squares) had no effect on peak height. (b.) The latency to peak DA concentration following stimulation onset was normalized for each rat and expressed as percent change from the average of the 3 baseline samples. Bupropion (filled circles) caused a significant increase in latency to 5min after injection through the duration of the experiment. Injection of either saline (open circles) or MSI-1436 (closed squares) had no effect on peak height. In both graphs, data points represent group means and error bars denote ±1S.E.M.